PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsPrecision medicine approach effective in lung cancer

BioNews

Precision medicine approach effective in lung cancer

Published 24 August 2015 posted in News and appears in BioNews 816

Author

Kirsty Oswald

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Researchers have shown that a skin cancer drug can be used to treat advanced lung cancer in patients whose tumours harbour a particular mutation...

Researchers have shown that a skin cancer drug can be used to treat advanced lung cancer in patients whose tumours harbour a particular mutation.

The results come from a personalised medicine trial which set out to treat patients, not on the basis of their cancer site or type, but by the types of mutations found in their tumours.

'This study is the first deliverable of precision medicine. We have proven that histology-independent, biomarker-selected basket studies are feasible and can serve as a tool for developing molecularly targeted cancer therapy,' said Dr José Baselga, the study's senior author from Memorial Sloan Kettering Cancer Center in New York. 'While we can - and should - be cautiously optimistic, this is what the future of precision medicine looks like.'

The researchers treated 122 patients with the metastatic melanoma drug vemurafenib. All the patients tumours tested positive for the BRAF V600 mutation the drug targets - one that is common in skin cancer but rarer in other cancers.

In the 20 patients with non-small-cell lung cancer, 42 percent responded to the drug and the median progression-free survival time was 7.3 months, the researchers report in the New England Journal of Medicine.

The strategy also showed efficacy in two rare conditions involving white blood cell overproliferation, Erdheim-Chester disease and Langherhans cell histiocytosis, where the response rate was 43 percent. And, despite a median treatment duration of 5.9 months, no patients progressed during therapy.

However, results for other cancer types were more modest with smaller or no effects seen in patients with colorectal cancer, brain tumours, multiple myeloma, anaplastic thyroid cancer or bile duct cancer.

Dr Otis Brawley, chief medical officer of the American Cancer Society, who was not involved in the study, told Reuters the research provided 'proof-of-concept': 'We are going to see more and more things like this - someone with colon cancer who didn't do well with the normal treatment may get their tumour analysed and (one) of these small molecule drugs the FDA has approved for some other cancer might be tried.'

Studies that take such an approach, like this one, are sometimes called 'basket trials' and are becoming more common.

However, in an editorial accompanying the study, Professors David Hunter and Ralph D'Agostino argue that they should be seen only as a first step. Basket trials are hindered by factors such as small sample sizes, no comparator groups and the difficulty of identifying which mutations in a particular tumour are actually responsible for driving the disease, they say.

They argue that establishing open-access databases of off-label drug use may yield more useful and significant data.

'Developing such observational databases is far from trivial, but the costs per patient would be small in relation to the monthly costs of many of the targeted therapies,' they write. 'Perhaps the plural of anecdote could be data after all.'

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
26 February 2018 • 2 minutes read

FDA okays test for many cancer-causing genes

by Theofanis Michailidis

The US Food and Drug Administration has approved a test which can detect cancer-causing mutations in 324 genes...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
31 July 2017 • 3 minutes read

First personalised vaccines shows promise for skin cancer

by Meetal Solanki

A revolutionary vaccine uses the patient’s own immune response to target tumour cells and could be the first step in bespoke, precision medicine. 

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
12 June 2017 • 2 minutes read

FDA gives go-ahead to first cancer drug based on genetics

by Shaoni Bhattacharya

The first cancer drug based on a specific genetic feature has been approved by the US drugs regulator...

PET BioNews
News
8 May 2017 • 2 minutes read

Rapid blood test could detect lung cancer

by Meghna Kataria

A blood test could swiftly detect gene mutations found in lung cancer, allowing faster commencement of treatment...

PET BioNews
News
19 September 2016 • 2 minutes read

Personalised medicine leads to better cancer outcomes

by Rachel Reeves

Genetic sequencing leading to targeted treatment significantly improves cancer patient outcomes in early-stage clinical trials, according to a study...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
19 September 2014 • 2 minutes read

'Personalised' skin cancer drug wins NICE approval

by Dr Lanay Griessner

A skin cancer drug designed to be effective in patients whose cancer is driven by a specific gene mutation has been recommended by the National Institute for Health and Care Excellence to treat patients with advanced melanoma...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
23 August 2013 • 2 minutes read

Genetics gets to root of redhead skin cancer risk

by James Brooks

The genetic mutation responsible for red hair leaves DNA in skin cells more prone to sun damage and cancer, scientists report...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 March 2013 • 2 minutes read

Pair of gene-targeted melanoma drugs show promise in late-stage clinical trials

by Dr Tamara Hirsch

Two drugs targeting advanced melanoma linked to a mutation in the BRAF gene are more effective than current chemotherapy at slowing the progress of the skin cancer, clinical trial results indicate...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
31 January 2013 • 2 minutes read

European approval for skin cancer drug that could double lifespan

by Dr Louisa Petchey

The European approval of a new gene-specific drug for an aggressive form of skin cancer marks another step towards an era of personalised medicine. A recent trial showed promising results, with the drug shrinking tumour size and extending life span...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 November 2012 • 2 minutes read

Gene mutation melanoma drug recommended for NHS use

by Maria Sheppard

A drug which prolongs life in a form of skin cancer associated with a genetic mutation has been recommended for use on the NHS...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Bipolar disorder linked to high intelligence

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

6 July 2022 • 1 minute read

Frozen embryo transfers linked to high blood pressure in pregnancy

5 July 2022 • 1 minute read

Anorexia in pregnancy linked to increased risk of complications

5 July 2022 • 2 minutes read

Pregnancy after breast cancer treatment does not increase risk of recurrence

5 July 2022 • 1 minute read

No difference between fresh and frozen sperm for IUI

4 July 2022 • 2 minutes read

Shorter IVF protocol reduces risk of OHSS

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856